APMA National Symposium Addresses Onychomycosis

Sponsored by Ortho Dermatologics. To learn more, click here. 

At a non-CECH symposium at the APMA National, Tracey Vlahovic, DPM, FFPM RCPS (Glasg) spoke about the clinical profile for JUBLIA (efinaconazole 10%) in the management of toenail onychomycosis. She shared clinical trial data in multiple categories including various patient populations, safety, efficacy, and special circumstances.

JUBLIA is a topical azole antifungal whose formulation reaches the site of onychomycosis via application on, around, and under the nail. Its indications are for onychomycosis due to Trychophyton rubrum and Trichophyton mentagrophytes. Interestingly, Dr. Vlahovic shared study results that demonstrated penetration of the medication even in when used in the presence of nail polish, disease (such as diabetes), and in cases of increased toenail thickness. She adds that there is also evidence of efficacy and safety for pediatric patients aged 6 to 16 years. Studies also showed that age and disease duration did not impact overall treatment results, although treating within one year of onset may improve outcomes. Lastly, Dr. Vlahovic shared that the most common adverse events included ingrown toenail and application site reactions.

Dr. Vlahovic discloses she is a consultant for Ortho Dermatologics. For more in-depth insights from Dr. Vlahovic on onychomycosis and the use of efinaconazole, click on these links to learn more. 

Key Insights on the Use of JUBLIA (efinaconazole) 10% for Onychomycosis

A Deeper Dive Into Specialized Aspects of Onychomycosis Treatment

Important Aspects of Evaluating Onychomycosis and Potential Stumbling Blocks